Skip to main content
. Author manuscript; available in PMC: 2024 Sep 1.
Published in final edited form as: J Control Release. 2023 Aug 14;361:470–482. doi: 10.1016/j.jconrel.2023.07.045

Figure 2. In silico and in vitromodels prioritize pairwise drug synergy between MRX-2843 and vincristine among screened combinations.

Figure 2.

a) Comparison of higher order (3-drug) and lower order (2-drug) synergy models to high-throughput combination drug screening data indicates that experimentally observed drug synergy is predominantly attributable to pairwise drug interactions. b) Comparison of expected (dashed) and observed (solid) Jurkat (T-ALL) cell viability following exposure to continuous pairwise drug gradients demonstrates that MRX-2843 and vincristine are most consistently synergistic. (a) Data points show 378 triplet drug combination responses measured in T- and ETP-ALL cell lines (n=6) via HTS. Data in (b) represent mean cell viability (72 h) as measured by nuclear dye exclusion.